Immatics Biotechnologies Revenue and Competitors
Estimated Revenue & Valuation
- Immatics Biotechnologies's estimated annual revenue is currently $120.2M per year.
- Immatics Biotechnologies's estimated revenue per employee is $281,400
- Immatics Biotechnologies's total funding is $446.2M.
Employee Data
- Immatics Biotechnologies has 427 Employees.
- Immatics Biotechnologies grew their employee count by 17% last year.
Immatics Biotechnologies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $17.7M | 88 | 7% | N/A | N/A |
#2 | $89.4M | 445 | 9% | N/A | N/A |
#3 | $32.4M | 161 | 25% | N/A | N/A |
#4 | $44.4M | 221 | 7% | N/A | N/A |
#5 | $120.2M | 427 | 17% | $446.2M | N/A |
#6 | $54.3M | 270 | 10% | N/A | N/A |
#7 | $49.6M | 247 | 52% | N/A | N/A |
#8 | $21.9M | 109 | -1% | N/A | N/A |
#9 | $16.5M | 82 | 4% | N/A | N/A |
#10 | $26.7M | 133 | 25% | N/A | N/A |
What Is Immatics Biotechnologies?
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics'? proprietary and world-leading XPRESIDENT® technology. Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients. QUICK FACTS - 150 Team members - >100 Targets covering 20 major solid and liquid tumors - About 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - Multiple partnered programs - Raised more than $230m in cash in five financings Read more about Immatics on our homepage: https://immatics.com/ Find us on Twitter and XING: Twitter: http://bit.ly/2DFbPre XING: http://bit.ly/2E1Kkpv Legal notice: https://immatics.com/legal-notice.html
keywords:N/A
$446.2M
Total Funding
427
Number of Employees
$120.2M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immatics Biotechnologies's People
| Name | Title | Email/Phone |
|---|---|---|
1 | IT Director | Reveal Email/Phone |
2 | Associate Manager | Reveal Email/Phone |
3 | Associate General Counsel | Reveal Email/Phone |
4 | General Counsel and Corporate Secretary | Reveal Email/Phone |
5 | SVP CMC | Reveal Email/Phone |
6 | CLIA Director | Reveal Email/Phone |
7 | Senior Research Associate | Reveal Email/Phone |
8 | Senior Scientist | Reveal Email/Phone |
9 | Senior Director Global Quality Operations | Reveal Email/Phone |
10 | IT Specialist II | Reveal Email/Phone |
Immatics Biotechnologies News
Immatics Biotechnologies. Immunovative Therapies. Bristol-Myers Squibb Company. Gritstone Oncology. NantKwest and More . Global Precision Medicine Market...
immatics biotechnologies; Immunicum; Ono Pharmaceutical; Onyx Therapeutics; Oxford BioMedica; Prometheus Laboratories; Seattle Genetics; Taiwan Liposome; Tracon...
... Novartis AG, Onyx Pharmaceuticals, Pfizer, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Exelixis.
Interim data update at SITC for ongoing ACTengine® IMA203 trial targeting PRAME demonstrated clinical responses across multiple solid tumor types during dose escalation phase Immatics to initiate three expansion cohorts for IMA203 targeting PRAME: monotherapy, combination with checkpoint inhibit ...
The deal includes a $75 million investment in the company by Celgene. Immatics would develop TCRs against solid tumor cancers using its in-house technology. It would be responsible for their development and validation through the lead candidate stage, at which point Celgene would have opt-in rig ...
Other Companies in Tuebingen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $111M | 552 | 24% | N/A |